Nurix Therapeutics, Inc. (NASDAQ:NRIX - Get Free Report) rose 4.4% on Thursday . The company traded as high as $14.32 and last traded at $14.52. Approximately 77,123 shares changed hands during trading, a decline of 91% from the average daily volume of 855,801 shares. The stock had previously closed at $13.90.
Analyst Ratings Changes
Several analysts have issued reports on NRIX shares. Royal Bank of Canada upped their target price on Nurix Therapeutics from $26.00 to $27.00 and gave the company an "outperform" rating in a report on Wednesday, January 29th. Leerink Partners started coverage on shares of Nurix Therapeutics in a research report on Monday, March 17th. They set a "market perform" rating and a $16.00 price objective for the company. Leerink Partnrs upgraded shares of Nurix Therapeutics to a "hold" rating in a report on Monday, March 17th. BTIG Research assumed coverage on shares of Nurix Therapeutics in a research note on Tuesday, December 10th. They issued a "buy" rating and a $35.00 price target for the company. Finally, Stephens reaffirmed an "overweight" rating and set a $31.00 price target on shares of Nurix Therapeutics in a research report on Tuesday, January 21st. Three equities research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $30.88.
Get Our Latest Research Report on NRIX
Nurix Therapeutics Price Performance
The firm has a market cap of $1.01 billion, a PE ratio of -4.59 and a beta of 2.18. The company's 50 day moving average price is $17.00 and its 200 day moving average price is $20.74.
Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last issued its quarterly earnings results on Tuesday, January 28th. The company reported ($0.75) EPS for the quarter, missing the consensus estimate of ($0.67) by ($0.08). Nurix Therapeutics had a negative net margin of 354.85% and a negative return on equity of 53.65%. Sell-side analysts expect that Nurix Therapeutics, Inc. will post -2.99 earnings per share for the current fiscal year.
Insider Buying and Selling
In other news, CFO Houte Hans Van sold 2,811 shares of Nurix Therapeutics stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $19.85, for a total value of $55,798.35. Following the completion of the transaction, the chief financial officer now owns 39,549 shares in the company, valued at approximately $785,047.65. This trade represents a 6.64 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Gwenn Hansen sold 3,690 shares of the company's stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $19.85, for a total transaction of $73,246.50. Following the sale, the insider now owns 55,937 shares in the company, valued at $1,110,349.45. The trade was a 6.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 12,326 shares of company stock valued at $213,449 in the last three months. 7.20% of the stock is owned by corporate insiders.
Hedge Funds Weigh In On Nurix Therapeutics
A number of institutional investors and hedge funds have recently modified their holdings of the company. JPMorgan Chase & Co. lifted its holdings in Nurix Therapeutics by 85.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 68,148 shares of the company's stock worth $1,531,000 after buying an additional 31,352 shares during the last quarter. Barclays PLC lifted its stake in Nurix Therapeutics by 77.9% during the third quarter. Barclays PLC now owns 128,344 shares of the company's stock worth $2,884,000 after purchasing an additional 56,190 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. boosted its holdings in Nurix Therapeutics by 42.7% in the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 789,222 shares of the company's stock valued at $14,869,000 after purchasing an additional 235,971 shares in the last quarter. FMR LLC boosted its holdings in Nurix Therapeutics by 675.9% in the third quarter. FMR LLC now owns 586,902 shares of the company's stock valued at $13,188,000 after purchasing an additional 511,256 shares in the last quarter. Finally, Dynamic Technology Lab Private Ltd purchased a new position in Nurix Therapeutics in the third quarter valued at approximately $530,000.
About Nurix Therapeutics
(
Get Free Report)
Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.
See Also
Before you consider Nurix Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nurix Therapeutics wasn't on the list.
While Nurix Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
